| Literature DB >> 31566580 |
Victoria Langer1, Eugenia Vivi1, Daniela Regensburger1, Thomas H Winkler2, Maximilian J Waldner3, Timo Rath3, Benjamin Schmid4, Lisa Skottke1, Somin Lee5, Noo Li Jeon5, Thomas Wohlfahrt6, Viktoria Kramer3, Philipp Tripal4, Michael Schumann7, Stephan Kersting8, Claudia Handtrack8, Carol I Geppert9, Karina Suchowski10, Ralf H Adams11, Christoph Becker3, Andreas Ramming6, Elisabeth Naschberger1, Nathalie Britzen-Laurent1, Michael Stürzl1.
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with rising incidence. Diseased tissues are heavily vascularized. Surprisingly, the pathogenic impact of the vasculature in IBD and the underlying regulatory mechanisms remain largely unknown. IFN-γ is a major cytokine in IBD pathogenesis, but in the context of the disease, it is almost exclusively its immune-modulatory and epithelial cell-directed functions that have been considered. Recent studies by our group demonstrated that IFN-γ also exerts potent effects on blood vessels. Based on these considerations, we analyzed the vessel-directed pathogenic functions of IFN-γ and found that it drives IBD pathogenesis through vascular barrier disruption. Specifically, we show that inhibition of the IFN-γ response in vessels by endothelial-specific knockout of IFN-γ receptor 2 ameliorates experimentally induced colitis in mice. IFN-γ acts pathogenic by causing a breakdown of the vascular barrier through disruption of the adherens junction protein VE-cadherin. Notably, intestinal vascular barrier dysfunction was also confirmed in human IBD patients, supporting the clinical relevance of our findings. Treatment with imatinib restored VE-cadherin/adherens junctions, inhibited vascular permeability, and significantly reduced colonic inflammation in experimental colitis. Our findings inaugurate the pathogenic impact of IFN-γ-mediated intestinal vessel activation in IBD and open new avenues for vascular-directed treatment of this disease.Entities:
Keywords: Cytokines; Gastroenterology; Inflammatory bowel disease; Vascular Biology; endothelial cells
Mesh:
Substances:
Year: 2019 PMID: 31566580 PMCID: PMC6819119 DOI: 10.1172/JCI124884
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808